Effect of Maitake D-fraction on cancer prevention.
Nanba
H
H
Department of Microbial Chemistry, Kobe Pharmaceutical University, Japan.
Kubo
K
K
D000284:Administration, Oral; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use; D016588:Anticarcinogenic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001487:Basidiomycota / Q000737:chemistry*; D002273:Carcinogens / Q000009:adverse effects; D002277:Carcinoma / Q000188:drug therapy* / Q000517:prevention & control / Q000556:secondary; D018890:Chemoprevention; D005936:Glucans / Q000008:administration & dosage / Q000627:therapeutic use*; D007912:Lentinan / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008748:Methylcholanthrene / Q000009:adverse effects; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D016685:Mitomycin / Q000008:administration & dosage / Q000627:therapeutic use; D009368:Neoplasm Transplantation; D047071:beta-Glucans
D000903:Antibiotics, Antineoplastic; D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D002273:Carcinogens; D005936:Glucans; D047071:beta-Glucans; D007912:Lentinan; D016685:Mitomycin; D008748:Methylcholanthrene; C033363:beta-1,3-glucan